JPWO2023190827A5 - - Google Patents
Info
- Publication number
- JPWO2023190827A5 JPWO2023190827A5 JP2024512771A JP2024512771A JPWO2023190827A5 JP WO2023190827 A5 JPWO2023190827 A5 JP WO2023190827A5 JP 2024512771 A JP2024512771 A JP 2024512771A JP 2024512771 A JP2024512771 A JP 2024512771A JP WO2023190827 A5 JPWO2023190827 A5 JP WO2023190827A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- sequence shown
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022057542 | 2022-03-30 | ||
| PCT/JP2023/013095 WO2023190827A1 (ja) | 2022-03-30 | 2023-03-30 | ｐＨ依存性抗硫酸化グリコサミノグリカン抗体及び抗体薬物複合体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPWO2023190827A1 JPWO2023190827A1 (https=) | 2023-10-05 |
| JPWO2023190827A5 true JPWO2023190827A5 (https=) | 2026-04-14 |
Family
ID=88202771
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024512771A Pending JPWO2023190827A1 (https=) | 2022-03-30 | 2023-03-30 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250163175A1 (https=) |
| EP (1) | EP4501967A1 (https=) |
| JP (1) | JPWO2023190827A1 (https=) |
| KR (1) | KR20240164795A (https=) |
| CN (1) | CN118891288A (https=) |
| AU (1) | AU2023243165A1 (https=) |
| CA (1) | CA3252516A1 (https=) |
| MX (1) | MX2024011373A (https=) |
| TW (1) | TW202346338A (https=) |
| WO (1) | WO2023190827A1 (https=) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7276855B2 (ja) | 2017-06-20 | 2023-05-18 | サヴィッド・セラピューティックス株式会社 | 抗硫酸化グリコサミノグリカン抗体 |
| BR112020019083A2 (pt) * | 2018-03-21 | 2020-12-29 | Five Prime Therapeutics, Inc. | Anticorpos, ácido nucleico, composições, célula e métodos para preparar um anticorpo, para tratar câncer, para tratar uma doença infecciosa, para tratar uma inflamação, para a identificação de um anticorpo, para melhorar a eficácia antitumoral de um anticorpo, para melhorar a farmacocinética de um anticorpo, para selecionar um anticorpo, para melhorar a eficácia de anticorpos, para isolar anticorpos, para detectar vista em uma amostra e para tratar câncer |
| JP2022057542A (ja) | 2020-09-30 | 2022-04-11 | 株式会社大都技研 | 遊技台 |
-
2023
- 2023-03-30 US US18/841,454 patent/US20250163175A1/en active Pending
- 2023-03-30 CN CN202380025801.0A patent/CN118891288A/zh active Pending
- 2023-03-30 MX MX2024011373A patent/MX2024011373A/es unknown
- 2023-03-30 CA CA3252516A patent/CA3252516A1/en active Pending
- 2023-03-30 AU AU2023243165A patent/AU2023243165A1/en active Pending
- 2023-03-30 KR KR1020247034433A patent/KR20240164795A/ko active Pending
- 2023-03-30 TW TW112112255A patent/TW202346338A/zh unknown
- 2023-03-30 JP JP2024512771A patent/JPWO2023190827A1/ja active Pending
- 2023-03-30 EP EP23780835.7A patent/EP4501967A1/en active Pending
- 2023-03-30 WO PCT/JP2023/013095 patent/WO2023190827A1/ja not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11819553B2 (en) | Glypican 3 antibodies and conjugates thereof | |
| Yurkovetskiy et al. | A polymer-based antibody–vinca drug conjugate platform: Characterization and preclinical efficacy | |
| CN102989000B (zh) | 制备美登木素生物碱抗体缀合物的方法 | |
| JP2025016545A5 (https=) | ||
| ES2404304T3 (es) | Conjugados de maitansinoide DM1 con anticuerpo trastuzumab, unidos mediante un conector no escindible, y su uso en el tratamiento de tumores | |
| CN101466409B (zh) | 细霉素衍生物 | |
| EP4378958A3 (en) | High-affinity anti-mertk antibodies and uses thereof | |
| KR20220052960A (ko) | 표적화된 덴드리머 접합체 | |
| JP2025183203A5 (https=) | ||
| IL278244B1 (en) | Antibodies and bispecific antigen-binding molecules that bind HER2 and/or APLP2, conjugates and uses thereof | |
| KR20230065935A (ko) | 치료적 접합체 | |
| CN111655295A (zh) | 抗her2抗体药物偶联物在治疗尿路上皮癌中的用途 | |
| EP4642488A1 (en) | Antibody drug conjugates | |
| EP2804631A1 (en) | Surrobody cojugates | |
| JPWO2023190827A5 (https=) | ||
| JPWO2023280092A5 (https=) | ||
| RU2024129146A (ru) | pH-ЗАВИСИМОЕ АНТИТЕЛО К СУЛЬФАТИРОВАННОМУ ГЛИКОЗАМИНОГЛИКАНУ И КОНЪЮГАТ АНТИТЕЛО-ЛЕКАРСТВЕННОЕ СРЕДСТВО | |
| JPWO2022078523A5 (https=) | ||
| Singh et al. | Antibody‐Drug Conjugates: New Frontier in Cancer Therapeutics | |
| JPWO2023079057A5 (https=) | ||
| JPWO2022084560A5 (https=) | ||
| RU2025139405A (ru) | Противоопухолевые комбинации, содержащие конъюгаты антитела к ceacam5 и лекарственного средства, антитела к pd1/pd-l1 и антитела к ctla4 | |
| RU2025106730A (ru) | Конъюгат антитело-лекарственное средство и способ его получения и применения | |
| KR20240164795A (ko) | pH 의존성 항황산화 글리코사미노글리칸 항체 및 항체 약물 복합체 | |
| RU2024115286A (ru) | Противоопухолевые комбинации, содержащие конъюгаты антитела к ceacam5 и лекарственного средства и антитела к vegfr-2 |